INTRODUCTION
Antiphospholipid antibodies (aPL) are strongly associated with arterial and venous thrombosis (1) (2) (3) (4) (5) and with fetal loss thought to be due to vascular occlusion in the placenta (6) (7) (8) (9) . The mechanism of pathogenicity is uncertain, but a procoagulant activity is likely. No definitive explanation of aPL mechanism yet exists, although many possible mechanisms have been proposed, including crossreactivity with antiendothelial cell antibodies (I0, 11), inhibition of arachidonic acid release (12, 13) , and interference with thrombomodiulin (14, 15) , tissue plasminogen activator activity (16) , protein S (I7), or antithrombin III (18) . Evidence supporting each of these proposals is not definitive.
Four calcium-dependent phospholipid binding proteins [lipocortins (19) ], termed placental anticoagulant proteins (PAPs), have been isolated from placenta and other endothelial tissues and have been extensively characterized (PAP I through IV) (20) (21) (22) (23) . While cDNA and protein sequences for the placental anticoagulant proteins have been determined (22, 52, 53) , and PAP I has been cloned (22, 53) , the precise function(s) of these proteins in vivo remains unclear. The four PAPs differ in isoelectric point, molecular weight (32,000 to 36,000), and relative phospholipid affinity. While all four inhibit blood clotting and phospholipase A 2 activities, potency is a reflection of their measured affinities for anionic phospholipid vesicles. PAP I has the greatest affinity; PAP II, PAP Ill, and PAP IV bind phospholipid vesicles 2-fold, 3-fold, and 160-fold more weakly than PAP I, respectively (20, 21) .
PAPs may regulate inflammatory reactions through PLA 2 inhibition (51) and may function as vascular anticoagulants (21) (22) (23) . PAP 1, a 36-kd single-chain protein, has been demonstrated in erythrocytes, leukocytes, platelets, and extracellular fluids including plasma, amniotic fluid, and culture medium of endothelial cells (24, 25) . PAP I is present in placenta in greatest quantity (20) . By binding to anionic phospholipid, PAP I prevents binding of activated factor X and prothrombin, thus decreasing the rate of thrombin formation in vitro (20-23, 25, 26) . PAP I also inhibits the phospholipid-dependent factor VII-tissue factor activation of factors IX and X in vitro (27) .
The placental anticoagulant proteins are of interest because aPL also bind to anionic phospholipids.
The lupus anticoagulant (LAC), which by definition prolongs coagulation assays when mixed with normal plasma, is generally viewed as one part of the spectrum of antiphospholipid antibodies (28) (29) (30) (31) . While some controversy exists as to whether LAC and anticardiolipin antibodies are identical or different antibody populations, and as to which is a more sensitive or specific predictor for clinical complications, both are clearly associated with thrombosis and fetal loss (32) (33) (34) (35) . LAC prolongs phospholipiddependent coagulation assays by binding to phospholipid and reducing the amount of phospholipid available to clotting factors. This results in an inhibition of the prothrombinase complex activation of prothrombin which is reversible with addition of excess phospholipid (36) (37) (38) . Because of the similarity in in vitro anticoagulant mechanisms, and because a correction of the PAP 1-induced aPTT prolongation by addition of aPL has been suggested (39), we investigated the interaction of aPL with PAP I. We address the question of whether aPL and PAP I recognize the same phospholipid epitope and whether phospholipid binding with possible restructuring by aPL or PAP I removes available phospholipid from the system.
MATERIALS AND METHODS

Sera
IgG fractions from sera of 12 patients with hightiter IgG aPL (>35 GPL U/ml) and 8 normal controls were evaluated. IgG was isolated using a protein G-Sepharose 4B column (Zymen, San Francisco, CA). Antiphospholipid activity was measured by ELISA.
Coagulation Assays
Kaolin Clotting Time (KCT). KCT was performed using pooled platelet-free plasma (PFP) as described by Exner (40) . PFP was prepared by cellulose acetate filtering (Nalgene, Rochester, NY) of platelet poor plasma. KCT was performed by incubation of PFP (100 p.1) with 50 ~1 acidwashed kaolin [20 mg/ml (Fisher Scientific, Fair Lawn, NJ)] for 3 rain at 37°C, followed by the addition of 100 ~1 0.025 M CaCI2, with the time until clot formation measured. All KCTs were done in duplicate. Anticoagulant activity was defined as KCT greater than the mean normals plus 3 standard deviations.
To test anticoagulant activity of column fractions, 50 p~l of Tris buffer A (50 mM Tris-HCl, pH 7.9, with 50 mM NaCl) or 50 Vd of column fraction was added to the PFP before testing. To test anticoagulant activity of IgG, 100 ~l of either normal or aPL-positive IgG (5-12 mg/ml) or 100 ~l of Tris buffer A (as a control for dilutional effect) was added to the PFP. To test for the combined effect of IgG and PAP I, 240 ng of PAP I (final concentration, 600 ng/ml) or Tris buffer A was added before the addition of kaolin.
Dilute Activated Partial Thromboplastin Time (aPTT). aPTT was performed using Actin FSL reagent (American Dade, Aguada, Puerto Rico) at a 1:4 dilution. Twenty-five microliters of Actin FSL reagent (incubated at 37°C for 1 min) was added to 100 ~1 of PFP and incubated for 3 min at 37°C. One hundred microliters of 0.025 M CaC12 was added and the time until clot formation measured. To test anticoagulant activity of IgG with and without PAP I, 100 I~l of normal or aPL-positive IgG and 50 Ixl of Tris buffer A or PAP I (final concentration, 5 I~g/ml) were added to PFP before incubation. To demonstrate reversibility of anticoagulant effect with phospholipid excess, aPL IgG, PAP I, and both in combination were also tested with addition of cardiolipin (CL) vesicles. CL vesicles were prepared by evaporation of CL in ethanol under nitrogen, addition of Tris buffer A, and sonication. Sixty-five microliters of a 1 mg/ml solution of CL vesicles, or 65 vd of Tris buffer A as control, was added.
Placental Anticoagulant Protein I: Isolation and Characterization
Human PAP I was isolated and purified using the method of Funakoshi et al. (23) with some modification. One hundred twenty-five grams of fresh human placenta was chopped, washed in Tris buffer A with EDTA and benzamidine, and homogenized. After filtering, ammonium sulfate was added to the filtrates to 40% saturation, followed by a second precipitation at 80% saturation. The precipitate was dissolved in Tris buffer A, dialyzed, added to DEAE-Sepharose CL-6B (Pharmacia LKB Biotechnology, Piscataway, N J), and eluted with a linear gradient formed by Tris buffer A and Tris buffer A plus 0.45 M NaC1. Fractions were assayed for protein concentration (absorbance at 280 nm with spectrophotometer) and anticoagulant activity (KCT). Active fractions were pooled and precipitated with 80% saturated ammonium sulfate, dis-solved in Tris buffer B (50 mM Tris, pH 7.9, with 0.2 M NaC1), and applied to a Sephadex G-75 column (Pharmacia LKB Biotechnology, Piscataway, N J). Trace albumin was removed with an albumin affinity filter (Affinity Technology Inc., Leonia, N J). The concentration of purified PAP I was determined by the Bradford method (41). PAP I was characterized on 10% sodium dodecyl sulthte (SDS)-polyacrylamide gel electrophoresis (PAGE) under nonreducing conditions (42) and by western blot technique (43) .
Anti-PAP I Antibody
Anti-PAP I antibody was raised in NIH/Swiss mice by immunization with 100 ~g of purified human PAP I in Freund's adjuvant at 2-week intervals for a total of three injections. To ensure specificity, antisera were immunoabsorbed against cross-linked human plasma proteins (44) . Specificity was confirmed by immunoblotting technique and ELISA (including inhibition studies with preincubation with PAP I which showed complete inhibition of anti-PAP I activity).
Antiphospholipid ELISA
APL ELISA was performed using the method of Gharavi et al. (45) . IgGs were tested at 50 t~g/ml in 10% adult bovine serum (ABS) in phosphatebuffered saline, pH 7.4 (PBS). When PAP I effect on aPL activity was evaluated, the assay was performed in the presence of 1.0, 2.5, and 7.0 mM CaC12.
PAP I ELISA
Phospholipid binding of PAP I to cardiolipin (CL) in solid phase was assayed by ELISA. Microtiter plates coated with cardiolipin in ethanol (50 ~g/ml) were blocked with 2% bovine serum albumin (BSA) in Tris buffer C (50 mM Tris-HCl, pH 7.9, 50 mM NaCI, and 10 mM CaClz). All washes and dilutions were with Tris buffer C unless otherwise noted. Serial dilutions of PAP I in 10% ABS-Tris buffer C (15 to 250 p~g/ml) were incubated for 2.5 hr (final calcium concentration, 2.5 mM). Mouse anti-human PAP I antibody in 2% human serum albumin (HSA)-Tris buffer C (1/100) was applied, followed by goat anti-mouse IgG alkaline-phosphatase conjugated antibody (Sigma Chemical Company, St. Louis, MO) in 10% ABS-Tris buffer C (1/1000).
Color development with p-nitrophenyl phosphatase, 1 mg/ml, in diethanolamine buffer was read at 405 nm.
The effect of normal and aPL IgG on PAP I binding to CL on ELISA plate was evaluated using 350 and 575 I~g/ml IgG with a constant concentration of PAP I (100 p~g/ml) in 10% ABS-Tris buffer C (final CaC12, 2.5 mM) in the ELISA system described above. Eleven aPL and eight normal IgGs were tested at each concentration.
Absorption and Inhibition Studies
PAP I binding to phospholipid (PL) vesicles was tested by absorption studies. PL vesicles of phosphatidylserine (PS) and phosphatidylcholine (PC), 10 mg/ml, were prepared in the presence of either CaCI 2 or EDTA at PS/PC molar ratios of 0/100 and 20/80. [PAP I does not bind to pure PC, but does bind to vesicles at a 20/80 PC/PS ratio (23, 25, 26) . Pure PS vesicles could not be generated in the presence of calcium: PC of at least 20% is needed to stabilize a lamellar configuration (46) ].
PL in chloroform was evaporated under nitrogen, buffer added, and the sample sonicated. Vesicles (50 to 350 ~1) were incubated with PAP I (40 ~g/ml) and centrifuged at 14,000 rpm, and the resulting aqueous layer was separated and applied to a microtiter plate. After overnight incubation at 4°C, the plate was blocked with 2% BSA-Tris buffer C, followed by application of anti-human PAP I antibody in 2% HSA-Tris buffer C (1/100) and antimouse IgG alkaline phosphatase-conjugated antibody in 10% ABS-Tris buffer C (1/i000). Color development was read as above. Percentage of PAP I absorbed to PL vesicles was calculated using ELISA optical density (OD): 
Statistical Analysis
Clotting times and aPL and normal IgG effect on PAP I-phospholipid binding were evaluated using Student's t test for unpaired sample means. The PAP I effect on aPL-phospholipid binding was analyzed using Student's t test for paired samples.
RESULTS
PAP I Isolation and Characterization
In both column separations, anticoagulant activity followed the major protein peak (Fig. I) as previously described (23) . SDS-PAGE (10%) revealed two bands at 35 and 65 kd under nonreducing conditions ( Fig. 2A) , representing monomeric protein and dimer (31) . Coomassie blue staining determined purity of the final PAP I to be greater than 95%, and immunoblot using anti-PAP I antibody confirmed the protein identity (Fig. 2B ). 
Normal and aPL IgG
The mean optical density (OD) at 405 nm for normal IgGs was 0.138 ---0.021 (range, 0.133-0.172) and that for aPL IgGs was 1.259 ---0.682 (range, 0.413-2.242). Normal and aPL IgG means differed significantly (P < 0.001). Binding of a panel of five aPL IgGs and one normal IgG did not differ significantly when phosphatidylserine (PS), 50 I~g/ml, was used as antigen in aPL ELISA instead of cardiolipin (CL).
Coagulation Assays
All 12 aPL IgGs demonstrated anticoagulant activity. The KCT means of the aPL and normal IgGs differed significantly. PAP I markedly prolonged the clotting time of PFP, and addition of aPL IgG but not normal IgG significantly enhanced prolongation of the clotting time (Table I) . When increasing quantities of aPL IgG (0 to 200 ixg/ml) were added to PFP with a constant amount of PAP I (240 ng), aPL IgG alone showed a plateau in KCT at approximately 200 sec at concentrations ->100 ixg/ml, and addition of PAP I at each concentration of aPL IgG caused further prolongation of KCT, up to 420 sec. The dilute aPTT assay confirmed the KCT resuits. APL IgGs again produced additive prolongation of the aPTT when incubated with PAP I (Table  II) (Fig. 3) . Inhibition by PAP I was calculated using calcium-containing controls since calcium affects aPL binding to CL (47): decreased aPL IgG binding occurred in the presence of I, 2.5, and 7 m3/CaC12 in the absence of PAP I. PAP I at a low concentration (10 wg/ml) inhibited aPL binding in the presence of calcium in a dose-related manner, whereas at 80 ~g/ml PAP I inhibition was equal for each calcium concentration (Table III) . In contrast, 11 aPL IgGs did not inhibit the binding of 100 p.g/ml PAP I to CL-coated ELISA plates, even at a high IgG concentration. (20) , with characteristics including reversible calcium-dependent binding to anionic phospholipids (19, 48) and phospholipase A2 (PLA2) inhibition (49, 50) . Although PAP I, like all lipocortins, is predominantly intracellular, it has been demonstrated in extracellular fluids at low levels (24) and shown to bind membranes of platelets and activated macrophages (54) . PAP I may be released as a local anticoagulant, preventing intravascular coagulation and possibly representing an important factor in aPL associated thrombosis.
PAP I and aPL both bind anionic phospholipid necessary for activation of coagulation factors (36, 37) . Like PAP I, lupus anticoagulants (LAC) in vitro cause prolongation of coagulation which is enhanced in tests utilizing a minimum of phospholipid and may be abolished with the addition of excess phospholipid (38, 54, 55) .
Because clinical studies suggest that aPL functions as a procoagulant in vivo, we hypothesized that it might interfere with the anticoagulant action of PAP I and might, thus, act as an antianticoagulant. Realizing that the paradoxical in vitro LAC effect might preclude demonstration of in vivo interaction in coagulation assays, we also evaluated more specific solid-phase phospholipid binding interactions. There are reports that lupus anticoagulant and anticardiolipin activities of antiphospholipid antibodies can be separated (56, 57) , although not all authors agree (30, 58) . We did not address this issue, having chosen to use aPL-positive IgG fractions rather than aPL affinity purified on phospholipid vesicles to avoid the possibility of phospholipid contamination. We do not assume that our results reflect purified antiphospholipid antibody populations and, so, cannot ascribe results to one or the other antibody population. All IgG preparations we evaluated demonstrated both LAC and anticardiolipin activities after purification.
Although both aPL and PAP I are known to bind phospholipid, it is not clear that they would necessarily interact, since they may each recognize very different epitopes, or phases, of anionic phospholipids. If binding is to the same phospholipid epitope, aPL and PAP I could either effectively deplete the system of phospholipid or, alternatively, restructure the phospholipid and enhance recognition by the other. Postulating such an interaction is not intuitive, since precise aspects of phospholipid binding for both proteins are incompletely defined. APL binding may be phase dependent (59) and wilt decrease with increasing calcium molarity (47), while PAP I binding to phospholipid is calcium dependent (53) .
Our data support an aPL-PAP I interaction in which competition for phospholipid does occur, since aPL and PAP I compete for phospholipid in both clotting assays and ELISA system. It is likely that phase preferences do not differ, if one assumes a uniform lipid phase distribution. In the coagulation assays we found a prolongation of clotting induced by all aPL IgGs, marked prolongation by PAP I, and further prolongation when aPL and PAP I were used together. Normal IgG and bovine albumin decreased the PAP I prolongation somewhat, probably due to a nonspecific steric hindrance effect. Our results contrast with a report suggesting that afffinity-purified aPL partially corrected a PAP I-induced aPTT prolongation (39) . Since aPL affinity purified with cardiolipin vesicles may contain contaminating phospholipid, we studied the effect of adding a small amount of cardiolipin vesicles to concentrated aPL IgG and demonstrated correction of aPL prolongation of the aPTT. The discrepancy between these data likely reflects addition of contaminating cardiolipin with affinitypurified aPL IgG.
The meaning of the further prolongation in KCT with PAP I when LAC effect of aPL IgG has plateaued is not self-evident but would be consistent with either differing avidities (with PAP I avidity greater), differences in the phospholipid or phospholipid complex recognized, or a combination of both. A difference in avidity is supported by the solid-phase phospholipid binding data. We found that aPL does not inhibit PAP I binding to phospholipid in vesicle form or on ELISA plates. This is consistent with several calculated avidities of PAP I for phospholipid (25, 53) . Ka estimates of <0.1 nM have been made, and PAP I is estimated to have a 1000-fold greater avidity for phospholipid than do coagulation factors. Pengo et al. (37) found that > I00 nM LAC IgG was required for prolongation of the dilute Russell viper venom time; in contrast, Tait et al. (25) and others (54) found prolongation of the less sensitive aPTT with PAP I in the nanomolar range, and we demonstrate here prolongation of the more sensitive KCT with picomolar amounts of PAP I.
The precise nature of aPL IgG and PAP I phospholipid binding and their competition may be even more complex. A serum cofactor which enhances IgG aPL binding has been identified as beta2-glycoprotein I (60-62), a constituent of normal serum. This cofactor may restructure phospholipid to make it more attractive to aPL. By experimental design, cofactor was present in our clotting assays and ELISA experiments. PAP I clearly does not function as a cofactor for aPL binding and may act by inhibiting beta2-glycoprotein I binding to phospholipid and reducing aPL binding through interference with the PL-cofactor complex rather than through direct competition with the antibody. Unlike PAP I, binding of beta2-glycoprotein I to anionic phospholipid is not calcium dependent. PAP I itself does not seem to require a cofactor for binding (23, 25, 53) .
It is not clear that PAP I inhibits binding of aPL to phospholipid in vivo. Physiologic interactions may be difficult to predict, given the possible effects of phospholipid phase, calcium molarity, aPL cofactor, and shift in local concentrations of PAP I and aPL. We do demonstrate an in vitro interaction in both coagulation assays and ELISA. The apparent competition for phospholipid suggests recognition of similar phospholipid epitopes: that PAP I inhibits aPL binding to phospholipid but aPL does not block PAP I binding more likely reflects differing avidities than different binding sites. Further work will better define precise mechanisms of phospholipid binding underlying the aPL-PAP I interaction described here and may yield insight into the basis of aPL pathogenicity.
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